Eli Lilly and Co.

Lilly study: 1 in 5 Alzheimer's patients misdiagnosed

May 20, 2013
J.K. Wall
The study results, which will be released Monday afternoon, are part of Indianapolis-based Lilly’s campaign to get Medicare to pay for use of its brain imaging agent Amyvid.
More

Canada’s Supreme Court won’t hear Lilly appeal on Zyprexa

May 16, 2013
Bloomberg News
Eli Lilly claims recent decisions by Canadian courts invalidating 17 drug patents have made the country an outlier among major developed countries.
More

Lechleiter's surgery to repair heart goes as planned

May 14, 2013
Bloomberg News
Eli Lilly and Co. CEO John Lechleiter underwent a scheduled surgery Monday for a heart defect, and the repair to the aorta is functioning as intended, the Indianapolis-based drugmaker said.
More

Lilly stops development on cancer drug after failed study

May 10, 2013
Bloomberg News
The drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual sales by 2018.
More

Indiana firms lose ground on Fortune 500 list

May 7, 2013
Mason King
Five of the six Hoosier firms that appear in the 2013 rankings slipped from their positions in last year's list of the largest U.S. companies.
More

Lilly CEO to step down temporarily due to surgery

May 6, 2013
J.K. Wall
John Lechleiter has been suffering from a dilated aorta, Eli Lilly and Co. said Monday. Current CFO Derica Rice will take his place until later this summer.
More

Biosciences institute aims for $300M endowment

May 6, 2013
J.K. Wall
The effort to launch the Indiana Biosciences Research Institute got $25 million from the Legislature, but the life sciences institutions backing the effort have set their funding sights much higher.
More

Lilly's sales-force restructuring to affect 1,600-plus

May 6, 2013
J.K. Wall
Lilly will eliminate 1,624 positions from its U.S. sales force in July, according to a notice the company made to state officials. But some of those workers may be rehired by the firm.
More

Lilly taking hard look at Pfizer's new Viagra strategy

May 6, 2013
Associated Press
Major drugmakers, including Indianapolis-based Eli Lilly and Co., are closely watching Pfizer Inc.'s plan to sell Viagra directly to consumers. The bold move blows up the drug industry's distribution model.
More

Lilly suing J&J for patent rights in Alzheimer's drug race

April 25, 2013
Bloomberg News
Eli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer’s disease.
More

Eli Lilly's profit shoots up despite lackluster sales

April 24, 2013
 IBJ Staff and Associated Press
The Indianapolis pharmaceutical company left its full-year profit forecast unchanged despite a spike in first-quarter earnings. Revenue fell short of analyst expectations.
More

Lilly on the rise as investors run back to pharma stocks

April 22, 2013
J.K. Wall
Investors are gaining confidence in the ability of major drugmakers, including Eli Lilly and Co., to improve their pipelines of new products. The big pharma firms begin to report first-quarter earnings this week.
More

Lilly's $30.6M tax abatement request clears hurdle

April 18, 2013
 IBJ Staff
The pharmaceutical firm has $400 million in projects in the works for its facilities south of downtown. City officials have advanced its request for tax breaks to a public hearing and final consideration May 1.
More

Lilly seeks $30.6M in tax breaks on downtown projects

April 15, 2013
Mason King
Indianapolis development officials on Wednesday will weigh the 10-year requests from the pharmaceuticals giant related to a new manufacturing plant and improvements to existing operations downtown.
More

Analysts: Lilly faces 'ugly' period until its pipeline produces

April 15, 2013
J.K. Wall
Investor smiles about new experimental cancer drugs and an aggressive play for the animal health market in China turned to frowns after Lilly disclosed deep cuts to its U.S. sales force.
More

Expected revenue slump spurs Lilly to cut sales force

April 11, 2013
J.K. Wall
The Indianapolis pharmaceuticals giant said Thursday that it would lay off hundreds of U.S. sales reps, as it prepares for the loss of patent protection on two of its best-selling drugs.
More

Tyco: No proof Lilly thieves used security report

April 8, 2013
Associated Press
Lawyers for a security company being sued in the theft of $60 million worth of pharmaceuticals from an Eli Lilly and Co. warehouse in Connecticut say there's no proof the thieves used a report it prepared about security weaknesses in the building.
More

Lilly pulls back from proposals lowering takeover barriersRestricted Content

April 6, 2013
Greg Andrews
Fortunately, a Lilly takeover looks less likely today than it has in a long time—for both obvious and more subtle reasons.
More

Lilly warehouse thieves had security report, lawsuit says

April 2, 2013
Associated Press
A federal lawsuit contends that thieves who broke into an Eli Lilly and Co. warehouse in Connecticut three years ago and stole more than $60 million worth of drugs obtained a copy of a report that revealed weaknesses in the building's security system.
More

Lilly to spend $180M doubling size of Indy plant

April 2, 2013
The new investment will bring the plant's total price tag to $320 million as the pharmaceutical giant seeks to increase production of insulin and related products.
More

J&J wins OK for first in new class of diabetes drugs

March 31, 2013
Bloomberg News
Johnson & Johnson, the world’s largest seller of health-care products, won approval for the first in a new family of diabetes drugs, giving them the edge against rivals including Eli Lilly and Co. that are developing similar medicines.
More

Lilly, Boehringer submit diabetes drug to FDA

March 25, 2013
Associated Press
Eli Lilly and Co. said Monday that it has submitted a new type 2 diabetes treatment it is developing with German drugmaker Boehringer Ingelheim to the Food and Drug Administration.
More

Bonuses drive up compensation for Lilly's top brass

March 25, 2013
J.K. Wall
Eli Lilly and Co. granted larger bonuses to its top five executives early this year, which boosted their 2012 compensation anywhere from 3 percent to 8 percent.
More

Court may decide if drugmakers can pay to delay generics

March 25, 2013
Associated Press
Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for years, steep price declines.
More

Profits at center of biosimilars debate

March 18, 2013
J.K. Wall
House Bill 1315, which is scheduled for a Senate floor hearing on Monday, would require pharmacists to check with a patient’s physician before automatically substituting a generic version of a biotech drug for a brand-name version.
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT